Skip To Main Content
Loïg Gaugain on Muck Rack

Loïg Gaugain

As seen in: PLOS ONE
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Loïg

Contact Loïg, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France

|
By Loïg Gaugain, Hélène Cawston, Javier Sanchez Alvares, Pierre Nahon
| paperity.org
PLOS ONE, Jan 2023 This is a preview of a remote PDF: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280442&type=printable Loïg Gaugain, Hélène Cawston, Coline Dubois de Gennes, Javier Sanchez Alvares, Pierre Nahon, Benjamin Mazaleyrat, Clément Le Dissez. , PLOS ONE, 2023, Volume 18, Issue 1, DOI: 10.1371/journal.pone.0280442
Open in Who Shared View Duplicates (486) Issue with article?

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France

|
By Amaris Consulting, Hélène Cawston, Loïg Gaugain, Javier Sanchez Alvares
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Abstract Background and aims The IMbrave150 clinical trial assessed the efficacy and safety of atezolizumab in combination with bevacizumab (ATZ+BVA) versus sorafenib in adults with advanced/unresectable hepatocellular carcinoma, who have not received prior systemic treatment.
Open in Who Shared Issue with article?
See all 2 articles